Clinical Report: Retraction of Study on Chamaejasmin B and Melanoma

Overview

This report details the retraction of a study claiming that Chamaejasmin B reduces malignant traits in mouse melanoma cell lines. The retraction was due to ethical concerns regarding animal welfare and integrity of the reported data.

Background

The integrity of research findings is critical in the field of oncology, particularly when they involve potential therapeutic agents. This retraction highlights the importance of ethical oversight in preclinical studies and the adherence to approved protocols. Such breaches can mislead the scientific community and impact clinical practices.

Data Highlights

No numerical data is available due to the retraction of the study.

Key Findings

• The original study reported that Chamaejasmin B decreased malignant characteristics in melanoma cell lines.
• Concerns were raised about the integrity of the figures and ethical oversight of animal experiments.
• The authors acknowledged that tumor sizes exceeded internationally accepted animal welfare limits.
• The experiments did not adhere to the approved protocols by the Shihezi University Animal Care and Use Committee.
• The retraction was approved by the Chief Editors of Frontiers in Oncology.

Clinical Implications

Healthcare professionals should remain vigilant regarding the ethical standards of preclinical research. This case underscores the necessity for rigorous oversight to ensure that findings are both valid and ethically obtained, which is essential for the advancement of safe and effective cancer therapies.

Conclusion

The retraction of this study serves as a reminder of the critical importance of ethical compliance in research. It emphasizes the need for transparency and integrity in scientific reporting.

References

1. Editorial Office F, Frontiers, 2026 -- Retraction: Chamaejasmin B decreases malignant characteristics of mouse melanoma B16F0 and B16F10 cells
2. Basic Research in Cardiology — Elimination of tumors without anthracyclines in mice results in both functional and molecular recovery of the heart from cancer-related changes, unlike the prolonged effects of doxorubicin treatment.
3. Archives of Toxicology — The BH3 mimetic (±) gossypol triggers apoptosis and mitochondrial impairment in human A375 melanoma cells independent of ROS in vitro
4. Blood Cancer Journal — AV-65: A New Inhibitor of Wnt/β-catenin Signaling Demonstrates Efficacy in Halting Multiple Myeloma Progression in Murine Models
5. Archives of Toxicology — In Vitro Evaluation of Myricetin in Bulk and Nanoparticle Forms for Anticancer Activity in Lymphocytes from Multiple Myeloma Patients
6. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
7. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study - PubMed